Ciclosporin - Novartis

Drug Profile

Ciclosporin - Novartis

Alternative Names: Ciclosporin microemulsion - Novartis; Cyclosporin A microemulsion - Novartis; Cyclosporin microemulsion - Novartis; Cyclosporin modified - Novartis; Cyclosporine microemulsion - Novartis; Neoral; OLO400; Sandimmun Neoral; Sandimmune Neoral

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Developer Erasmus MC; Novartis
  • Class Antineoplastics; Antipsoriatics; Antirheumatics; Ciclosporins; Eye disorder therapies; Heart failure therapies; Neuroprotectants
  • Mechanism of Action Calcineurin inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Atopic dermatitis; Heart transplant rejection; Liver transplant rejection; Myasthenia gravis; Pancreas transplant rejection; Psoriasis; Renal transplant rejection; Rheumatoid arthritis; Transplant rejection
  • Discontinued Ulcerative colitis

Most Recent Events

  • 12 Jul 2016 No development reported - Phase-I for Psoriasis in Netherlands (Topical)
  • 30 Jul 2014 Discontinued - Phase-II for Ulcerative colitis in England (PO)
  • 30 Sep 2007 Preregistration for Atopic dermatitis in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top